{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06433505",
            "orgStudyIdInfo": {
                "id": "CA071-1005"
            },
            "organization": {
                "fullName": "Celgene",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants",
            "officialTitle": "A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-drug-levels-metabolism-and-excretion-and-absolute-bioavailability-of-bms-in-healthy-male-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-23",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09-23",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-23",
            "studyFirstSubmitQcDate": "2024-05-23",
            "studyFirstPostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celgene",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ],
            "keywords": [
                "BMS-986365",
                "Pharmacokinetics",
                "Absolute Bioavailability",
                "Healthy Male Volunteers",
                "CC-94676",
                "ADME"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: BMS-986365",
                        "Drug: [14C] BMS-986365"
                    ]
                },
                {
                    "label": "Part B - Arm 1",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: [14C] BMS-986409 + BMS-986410"
                    ]
                },
                {
                    "label": "Part B - Arm 2",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: [14C] BMS-986410 + BMS-986409"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BMS-986365",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "[14C] BMS-986365",
                    "description": "Specified dose on specified days.",
                    "armGroupLabels": [
                        "Part A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "[14C] BMS-986409 + BMS-986410",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part B - Arm 1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "[14C] BMS-986410 + BMS-986409",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part B - Arm 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed concentration (Cmax)",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Time of maximum observed concentration (Tmax)",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC (INF))",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Apparent terminal plasma half-life (T-HALF)",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Total body clearance (CLT)",
                    "description": "Part A",
                    "timeFrame": "Up to Day 15"
                },
                {
                    "measure": "Apparent total body clearance (CLT/F)",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Mean residence time (MRT)",
                    "description": "Part A",
                    "timeFrame": "Up to Day 15"
                },
                {
                    "measure": "Apparent volume of distribution (Vz)",
                    "description": "Part A",
                    "timeFrame": "Up to Day 15"
                },
                {
                    "measure": "Apparent volume of distribution (Vz/F)",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Absolute bioavailability (F)",
                    "description": "Part A",
                    "timeFrame": "Up to Day 15"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with Adverse Events",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Number of participants with Serious Adverse Events",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Number of participants with AEs leading to discontinuation",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Number of participants with Vital sign abnormalities",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Number of participants with electrocardiogram (ECG) abnormalities",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Number of participants with physical examination abnormalities",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                },
                {
                    "measure": "Number of participants with clinical laboratory abnormalities",
                    "description": "Part A and B",
                    "timeFrame": "Up to Day 60"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male participants as determined by no clinically significant deviations from normal in medical history, physical examination, 12-lead ECGs, or clinical laboratory determinations, as determined by the investigator\n* Participants will require a left ventricular ejection fraction of \\> 50% at screening.\n* Body mass index of 18.0 to 32.0 kg/m2, inclusive, at screening. Body mass index = weight(kg)/(height \\[m\\])2.\n\nExclusion Criteria:\n\n* Any current or recent significant acute or chronic illness.\n* Participants with a prior history of heart failure, ischemic heart diseases, serious cardiac arrythmias, or prolonged QTcF interval (\\> 450 ms) at screening.\n* Current or recent (within 3 months of intervention administration) gastrointestinal disease that could affect the absorption of study drug including cholecystectomy. Mild gastroesophageal reflux (even if managed with avoidance of food triggers) is exclusionary.\n* History of allergy to BMS-986365 or related compounds.\n\nOther protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact Center www.BMSStudyConnect.com",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain the NCT# and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Local Institution - 0001",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53704",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site 0001",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.BMSStudyConnect.com"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}